AAMS Neurology & Neurosciences · Vol. 7 · Issue 3 · 2026-03-01
Anti-CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Evidence From 15 Countries
Ashworth B, Türkoğlu R, Mizuno Y
University of Manchester, Manchester, UK; Istanbul University, Istanbul, Turkey; Keio University, Tokyo, Japan
Abstract
International real-world registry study analyzing treatment outcomes, adherence, and safety of anti-CGRP monoclonal antibodies in 12,500 patients with chronic migraine across 15 countries.
Keywords: chronic migraine, CGRP antibodies, real-world evidence, erenumab, fremanezumab
Full Text
International real-world registry study analyzing treatment outcomes, adherence, and safety of anti-CGRP monoclonal antibodies in 12,500 patients with chronic migraine across 15 countries.
This article is published open access by AAMS Neurology & Neurosciences. The complete peer-reviewed text can be read on the journal page.
Author Citation Metrics
Metrics are sourced from public bibliometric records (OpenAlex) and each author's Google Scholar profile.